Overview
U.S. biomedical innovator's 2025 sales rose 41%, driven by FemBloc product sales
Net loss for 2025 narrowed slightly, with EPS at ($0.47)
Company completed $12 mln financing
Outlook
Company expects current cash to fund operations into the third qtr of 2026
Result Drivers
FEMBLOC SALES - Co said 2025 sales growth was primarily due to sales of FemBloc
R&D EXPENSES - Research and development expenses decreased mainly due to commercialization of development products into inventory and reduced professional fees and compensation costs, partially offset by increased regulatory costs
Company press release: ID:nGNX9C5CFR
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$0.47
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Femasys Inc is $4.50, about 1,096.8% above its March 30 closing price of $0.38
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
